Imaging and AI in Retinal Clinical Trials

Yijun Huang, PhD, and David P. Bingaman, DVM, PhD, DACVO, discuss the role of centralized imaging services in ophthalmology trials and review new AI-based endpoints for AMD and GA.

By: Yijun Huang, PhD, David P. Bingaman, DVM, PhD, DACVO, Patricio G. Schlottmann, MD

Retinal Physician November 11, 2026

5 Key Takeaways

1

Merit provides independent, blinded image review for multisite global ophthalmology trials.
2

Merit also coordinates data interfaces with trial sites and uses a technology platform for stakeholder review and audit trails.
3

Merit described quality assurance as part of its work to check trial data.
4

Merit planned to present AI-based endpoints using en face OCT images for dry AMD and GA.
5

The endpoints discussed included GA lesion area and, in high-risk intermediate AMD, hyperreflective foci, drusen volume, and choroidal hypertransmission defects.

Yijun Huang, PhD

Co-founder and CEO

Affiliations: Merit CRO

Specialties: Ophthalmology

Bio: Yijun Huang, PhD, is the co-founder and CEO of Merit CRO, a U.S.-based reading center specializing in ophthalmology clinical trials. Under his leadership, Merit provides independent, blinded evaluations of multisite global clinical trial imaging data, essential for the reliable assessment of treatment efficacy in retinal diseases. Dr. Huang’s team integrates advanced technology platforms to facilitate stakeholder collaboration, ensure data quality, and maintain comprehensive audit trails. Dr. Huang has played a pivotal role in advancing the use of centralized imaging services and AI-derived endpoints in clinical trials for age-related macular degeneration and geographic atrophy. His work at Merit CRO underscores the importance of quality assurance and efficient data management in the conduct of ophthalmology studies worldwide.

Patricio G. Schlottmann, MD

Affiliations: Charles Centro Oftalmológico

Specialties: Ophthalmology

Bio: Patricio G. Schlottmann, MD, is an ophthalmologist associated with Charles Centro Oftalmológico in Argentina. He received his medical degree from the University of Buenos Aires in 1998 and completed formative clinical training at Santa Lucía Hospital in Buenos Aires, Argentina’s largest public eye hospital. Dr. Schlottmann’s work has centered on ophthalmic care, diagnostic technology, and clinical research. His interest in ocular imaging began during specialist training with exposure to Stratus OCT technology, which led to his first publication in Investigative Ophthalmology and Visual Science and helped shape a career combining clinical practice with research.

Imaging and AI in Retinal Clinical Trials

5 Key Takeaways

1

2

3

4

5

Recommendations